3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
18
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Cyclophosphamide
6
Vincristine
3
Temozolomide
3
Radiotherapy
3
Cisplatin
3
Automobiles
3
fludarabine
2
Etoposide
2
Eflornithine
2
Carboplatin
2
omburtamab I-131
1
ibrutinib
1
gallium Ga 68 dotatate
1
etoposide phosphate
1
belzutifan
1
Zoledronic Acid
1
Thiotepa
1
Tamoxifen
1
Standard of Care
1
Radiotherapy, Image-Guided
1
Pemetrexed
1
ONC206
1
Nivolumab
1
Mesna
1
Maintenance Chemotherapy
1
Lomustine
1
Isotretinoin
1
Induction Chemotherapy
1
Hydrocortisone
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
Sunitinib
×
1 year
×
Clear all
No trials found.